Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT04239170 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
84
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Peking University